FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis
South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that i...Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
Genentech, Inc. and XOMA Ltd. today announced positive results from a randomized Phase III clinical trial with Raptiva (efalizumab) that studied efficacy and safety in the treatment of adults with moderate-to-severe plaque psoriasis. The study results were presented by Kenneth Gordon, M.D., Associate Professor of Medicine, Division of Dermatology at Loyola University in Chicago, Illinois during...Results from open-label Raptiva study suggest continued benefit with long-term treatment
Genentech, Inc. and XOMA Ltd. today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous Raptiva (efalizumab) treatment in patients with moderate-to-severe psoriasis. ...... "The findings from this important open-label study on the long-term safety and efficacy of Raptiva are very encouraging and further support R...